
Margaret A. Chang
Articles
-
Oct 16, 2024 |
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Anti-VEGF for RVO: The Gold Standard John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.
-
Oct 16, 2024 |
consultantlive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
Shaping the Future of Retinal Vascular Disease Treatment - Episode 4Anti-VEGF for RVO: The Gold Standard Published on: October 16, 2024John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.
-
Oct 16, 2024 |
consultantlive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
Shaping the Future of Retinal Vascular Disease Treatment - Episode 3Faricimab for DME: Durability and Patient Outcomes Published on: October 16, 2024Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.
-
Oct 16, 2024 |
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Faricimab for DME: Durability and Patient Outcomes Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.
-
Oct 16, 2024 |
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Faricimab for nAMD: Key Trial Highlights and Case Example Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →